Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 11/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461199 | 0.98 | VCAM1 (0.58) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1897629 | 0.90 | CRHBP (0.58) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1896442 | 0.89 | ALDH1A1 (0.53) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1901253 | 0.89 | VCAM1 (0.53) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL10663504 | 0.87 | MAPT (0.66) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14956482 | 0.87 | VCAM1 (0.60) | VCAM1ALDH1A1 | |
| SCHEMBL1065964 | 0.86 | VCAM1 (0.51) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL8569064 | 0.84 | ALDH1A1 (0.53) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL4096354 | 0.83 | DHFR (0.68) | VCAM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3973969 | 0.82 | TSHR (0.69) | VCAM1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | VCAM1 931/4885MAPT 2833/4885MEN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.